VetMedGuide

Vet Med Guide

Companion animal in a veterinary practice workspace.
Practice2026-06-08 · 11 min read

Veterinary Drug Global Market Access: How Animal Health Products Cross Borders

How veterinary drugs move from one regulatory system to another — VICH harmonization, regional requirements, and what animal health companies navigate to bring products to market worldwide.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

The veterinary pharmaceuticals market was valued at approximately $28.98 billion in 2026 and is projected to reach $39.37 billion by 2031, driven by rising pet ownership, livestock production growth, and demand for newer anti-infectives, parasiticides, and biologic therapies. But behind every product that reaches a clinic shelf or an online pharmacy is a multi-year regulatory journey that varies by country — and in many cases, by species and indication.

For veterinary professionals, practice owners, and anyone working in animal health, understanding how veterinary drugs gain market access internationally matters. It explains why some products launch years later in certain regions, why label claims differ across borders, and why global supply chains remain fragmented even for major pharmaceutical companies.

Who regulates veterinary drugs — and where

There is no single global veterinary drug approval. Every country (or economic bloc) maintains its own regulatory authority, data requirements, and review timelines. The major regulators include:

Region Authority Scope
United States FDA Center for Veterinary Medicine (CVM) All animal drugs (NADA/ANADA pathway)
European Union EMA (CVMP) for centralized, national agencies for decentralized Veterinary medicinal products across EU member states
Japan Ministry of Agriculture, Forestry and Fisheries (MAFF) Veterinary drugs and feed additives
China National Medical Products Administration (NMPA) Veterinary drug registration and import approval
South Korea Ministry of Food and Drug Safety (MFDS) Veterinary drug approval and MRLs for food-producing animals
United Kingdom Veterinary Medicines Directorate (VMD) Post-Brexit standalone veterinary drug regulation
Canada Health Canada, Veterinary Drugs Directorate Veterinary drug approval
Australia APVMA (Australian Pesticides and Veterinary Medicines Authority) Both agricultural and veterinary chemicals

Each regulator requires evidence of product safety, efficacy, and manufacturing quality — but the specific studies, data formats, and review processes differ.

VICH: The foundation of regulatory harmonization

The International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), launched in 1996, is the primary framework for aligning veterinary drug registration requirements across the EU, Japan, and the United States. VICH is a trilateral program that includes both regulatory authorities and industry representatives.

VICH develops harmonized guidelines covering three pillars:

  1. Quality — manufacturing standards, stability testing, and pharmaceutical development data.
  2. Safety — target-animal safety, user safety, food safety (residue studies for food-producing animals), and environmental safety.
  3. Efficacy — clinical field trials, dose confirmation, and effectiveness studies.

As of 2026, VICH has produced over 50 harmonized guidelines. The World Organisation for Animal Health (WOAH, formerly OIE) participates as an associate member and supports the VICH Forum, which extends VICH principles to non-member countries in Africa, Asia, and Latin America — a critical effort given that many emerging markets still lack fully developed veterinary regulatory infrastructure.

A practical benefit of VICH harmonization: a well-designed pivotal study conducted to VICH standards can often satisfy data requirements in multiple jurisdictions simultaneously, reducing duplication and shortening development timelines for sponsors pursuing global registrations.

The U.S. pathway: NADA and ANADA

In the United States, the FDA CVM evaluates new animal drugs through the New Animal Drug Application (NADA) pathway for innovative products, and the Abbreviated New Animal Drug Application (ANADA) pathway for generic versions of previously approved drugs.

The NADA process requires:

  • Target-animal safety and efficacy studies demonstrating that the drug works as claimed and is safe at the labeled dose.
  • Human food safety data (for food-producing animals), including residue chemistry studies and toxicological evaluations that establish withdrawal periods.
  • Chemistry, manufacturing, and controls (CMC) documentation covering manufacturing processes, specifications, and stability.
  • Environmental assessment where required.

For generic animal drugs (ANADA), the sponsor must demonstrate bioequivalence to the reference listed new animal drug. The ANADA pathway has been instrumental in expanding access to affordable veterinary medications — including many of the generic antibiotics, NSAIDs, and anesthetics that general practices use daily.

In 2026, FDA CVM continued to approve new animal drugs at a steady pace. Recent approvals include firocoxib tablets for horses, Gastrobim (omeprazole) for equine gastric ulcers, and Florfinasone Otic (florfenicol, terbinafine, mometasone furoate) for canine otitis externa.

Europe: Centralized and decentralized routes

The European Union offers two primary pathways for veterinary drug authorization:

  • Centralized procedure via EMA's Committee for Medicinal Products for Veterinary Use (CVMP): mandatory for certain biotechnology-derived products and optional for innovative drugs seeking authorization across all EU member states simultaneously.
  • Decentralized and mutual recognition procedures: the applicant selects a Reference Member State, which conducts the initial assessment. Other Concerned Member States then mutually recognize or endorse that assessment.

The EU's regulatory framework is generally considered one of the most rigorous globally, with strong emphasis on environmental risk assessment and antimicrobial resistance (AMR) considerations for antibiotic products.

China's NMPA veterinary drug registration

China represents one of the fastest-growing veterinary pharmaceutical markets globally. According to industry data filed with the Hong Kong Stock Exchange, China's animal health market was valued at approximately RMB 68 billion (roughly $9.4 billion) in 2024 and is projected to reach RMB 79 billion by 2026, with the chemical and drug formulation segment accounting for the largest share.

Veterinary drug registration in China is overseen by the Ministry of Agriculture and Rural Affairs (MARA), with technical evaluation conducted by the China Institute of Veterinary Drug Control (IVDC) and its Center for Veterinary Drug Evaluation (CVDE). The regulatory framework is based primarily on the Regulations on the Administration of Veterinary Drugs and involves:

  • New veterinary drug registration requiring safety, efficacy, quality, and clinical trial data.
  • Import drug registration for products manufactured overseas, which requires both the foreign manufacturer's data and a China-based registration holder.
  • Re-registration required every five years, with applications submitted six months before expiry.
  • Classification of veterinary drugs into Categories I (new drugs), II (improved drugs), and III (generic copies), each with different data requirements.

China has been gradually aligning its regulatory framework with international standards. In 2026, MARA continued to refine veterinary drug registration requirements, including updates to classification criteria for companion animal health products — reflecting the rapid growth of China's pet healthcare sector.

For animal health companies evaluating market entry into China's veterinary pharmaceutical sector, ChinaMedGlobal provides China veterinary drug registration guidance and market-access strategy covering the MARA registration pathways, local license holder requirements, and the practical steps needed to move from dossier preparation to commercial launch.

South Korea's MFDS framework

South Korea's animal health market reached approximately $775.3 million in 2025 and is projected to grow to approximately $1.17 billion by 2033. Veterinary drug regulation falls under the Ministry of Food and Drug Safety (MFDS), with additional oversight from the Animal and Plant Quarantine Agency (APQA) for livestock drugs and the National Institute of Fisheries Science (NIFS) for aquaculture products.

Key features of the Korean system:

  • MRL setting: MFDS establishes maximum residue limits for veterinary drugs in food products. Import tolerances can be requested for drugs not registered domestically but used in exporting countries — the review process may take up to 12 months.
  • Joint review initiatives: In 2026, MFDS expanded regulatory harmonization efforts including joint reviews with EMA and Japan's PMDA, enabling faster parallel submissions.
  • Digital medical product regulation: Korea's Digital Medical Products Act entered into force in January 2025, with additional requirements (including labeling and health-support device rules) taking effect in January 2026. This affects veterinary digital health tools and software-as-medical-device products.

Why regulatory divergence matters for veterinary practice

From a clinic and practice perspective, international regulatory differences produce several real-world effects:

Product availability lag

A veterinary drug approved by the FDA in 2024 may not receive EMA approval until 2026 or later, and Chinese or Korean market access may follow on a different timeline entirely. This is why veterinarians in different countries have different formulary options for the same clinical problem — and why drug monographs on this site always specify the regulatory jurisdiction (typically U.S. FDA labeling unless otherwise noted).

Label claim differences

Even when the same active ingredient is approved in multiple markets, the specific label claims — approved species, indications, dosing intervals, and contraindications — may vary. A parasiticide labeled for 12 weeks of tick protection in one market may carry an 8-week label in another, based on the specific efficacy data submitted and reviewed in that jurisdiction.

Import alert exposure

The FDA maintains Import Alert 68-19, which lists unapproved animal drug products that may be detained at U.S. ports of entry. The list includes numerous products from Chinese and other overseas manufacturers — a reminder that the regulatory status of a product in its country of origin does not automatically confer legality in the destination market. Veterinary practices purchasing products from international online sources should verify that the product carries a valid FDA approval or index listing.

Generic drug access

The ANADA pathway in the U.S. and equivalent abbreviated pathways in other markets determine when affordable generic versions of veterinary drugs become available. Patent expiry, data exclusivity periods, and regional filing strategies all affect the timeline. For a practice managing drug budgets, the availability of generic meloxicam, omeprazole, or carprofen is a direct result of this regulatory machinery.

Several developments are reshaping how veterinary drugs move across borders:

VICH global outreach

The VICH Forum continues to expand participation beyond the founding EU-Japan-USA trio. As more countries adopt VICH-aligned guidelines, the data package supporting a new veterinary drug becomes more portable across markets — reducing the cost and time of multi-country registration.

WOAH's TRUVET platform

In 2026, WOAH launched the Track and Report Unsafe Veterinary Products (TRUVET) platform, a global surveillance system for substandard and falsified veterinary products. This initiative reflects growing recognition that regulatory approval is only effective when supply chains deliver genuine, quality-assured products to the point of use.

Biologics and monoclonal antibodies

The veterinary biologics landscape is evolving rapidly. Products like Cytopoint (lokivetmab, a caninized monoclonal antibody for allergic dermatitis) and Solensia (frunevetmab for feline OA pain) represent a new product class that sits at the intersection of biotechnology and traditional veterinary therapeutics. In the U.S., some biologics are regulated by USDA APHIS Center for Veterinary Biologics (CVB) under the Virus-Serum-Toxin Act rather than by FDA CVM — adding jurisdictional complexity for companies developing these products.

Antimicrobial stewardship regulation

Globally, regulators are tightening the rules around veterinary antimicrobial use. The EU has prohibited the routine preventive use of antibiotics in livestock. The FDA's Guidance for Industry #263 transitioned all remaining over-the-counter medically important antimicrobials to prescription status in the U.S. (effective June 2023). These regulatory shifts affect product availability and prescribing practices across all animal health markets.

What this means for veterinary professionals

For veterinarians and practice teams, the international regulatory landscape may seem distant from daily clinical work. But its effects show up in concrete ways:

  • Formulary options — what drugs are available, in what formulations, and at what cost — are shaped by which products have been registered in your market.
  • Label information — approved indications, safety warnings, and monitoring requirements — reflects the specific data package reviewed by your national regulator.
  • Generic availability — when lower-cost alternatives to branded drugs appear — depends on patent and data exclusivity timelines in your jurisdiction.
  • Imported product risks — products purchased from unverified international sources may lack valid local approval and could be subject to import detention.

Understanding the regulatory journey behind the products you prescribe does not make you a regulatory affairs specialist. It does make you a more informed prescriber — one who can explain to clients why a particular drug is or is not available, why label instructions should be followed, and why purchasing medications from authorized channels matters.

Sources

Topics
Practice Finance & ROIClinic Workflow & Operations
Related Articles